文献速递甲状腺与浅表泌尿生殖技术与安全PETCT

PSMA PET甲状腺偶发瘤发生率取决于分析方法和示踪剂

Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer.
PubMed 文献 · Eur Radiol · 2023-03-09

该研究回顾性分析了502例前列腺癌患者的PSMA PET/CT,比较结构化视觉分析、半定量分析(甲状腺/血池SUVmax比值≥2.0)及临床报告分析对甲状腺偶发瘤(PTI)检出率的影响。结果显示PTI发生率在视觉分析为22%、半定量分析为7%、临床报告分析为2%,且不同PSMA示踪剂间差异显著(如[18F]PSMA-1007为29-64%,[68Ga]PSMA-11为7-23%,[18F]DCFPyL为2-8%,[18F]PSMA-JK-7为0%)。结论认为PTI发生率高度依赖分析方法和示踪剂,建议将PTI限定为局灶性甲状腺摄取且SUVmax t/b比值≥2.0,临床随访需权衡原发病预期。

要点

  • PSMA PET甲状腺偶发瘤发生率因示踪剂和分析方法差异巨大,报告时需注明方法。
  • 建议将PTI定义为局灶性摄取且SUVmax t/b比值≥2.0,以减少弥漫性/轻度摄取的过度诊断。
  • PTI相关甲状腺不良事件发生率低,临床处理应结合前列腺癌预期预后权衡。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the incidences of prostate-specific membrane antigen (PSMA) thyroid incidentaloma (PTI) using different methods to define PTI, to compare the incidence of PTI among different PSMA PET tracers, and to evaluate the clinical consequences of PTI.

METHODS: PSMA PET/CT scans in consecutive patients with primary prostate cancer were analyzed for the presence of PTI using a structured visual (SV) analysis reporting any elevated thyroidal uptake; a semi-quantitative (SQ) analysis using a SUVmax thyroid/bloodpool (t/b) ratio ≥ 2.0 as cutoff; and an analysis of PTI incidence in the clinical reports (RV analysis).

RESULTS: A total of 502 patients were included. The incidence of PTIs was 22% in the SV analysis, 7% in the SQ analysis, and 2% in the RV analysis. PTI incidences differed significantly from 29 to 64% (SQ, resp. SV analysis) for [18F]PSMA-1007, 7 to 23% for [68Ga]PSMA -11, 2 to 8% for [18F]DCFPyL, and to 0% for [18F]PSMA-JK-7. The majority of PTI in the SV and SQ analyses consisted of diffuse (72-83%) and/or only slightly elevated thyroidal uptake (70%). Inter-observer agreement in the SV analysis was substantial (kappa = 0.76-0.78). During follow-up (median 16.8 months), there were no thyroid-related adverse events except in three patients.

CONCLUSIONS: The incidence of PTI varies greatly among different PSMA PET tracers and is strongly dependent on the analysis method applied. PTI may safely be restricted to focal thyroidal uptake with a SUVmax t/b ratio ≥ 2.0. The clinical pursuit of a PTI must be weighed up to the expected outcome of the underlying disease.

KEY POINTS: • Thyroid incidentalomas (PTIs) are recognized in PSMA PET/CT. • Incidence of PTI varies greatly among PET tracers and analysis methods. • Incidence of thyroid-related adverse events in PTI cases is low.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Donswijk, Piek, Cheung, et al. Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer. Eur Radiol. 2023. PMID: 36892644. doi:10.1007/s00330-023-09492-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。